Compare DNP & LGND Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | DNP | LGND |
|---|---|---|
| Founded | N/A | 1987 |
| Country | United States | United States |
| Employees | N/A | 68 |
| Industry | Investment Managers | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 4.0B | 3.7B |
| IPO Year | 1995 | N/A |
| Metric | DNP | LGND |
|---|---|---|
| Price | $10.62 | $227.24 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 7 |
| Target Price | N/A | ★ $247.29 |
| AVG Volume (30 Days) | ★ 645.2K | 189.3K |
| Earning Date | 01-01-0001 | 05-07-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | $1.25 |
| Revenue Next Year | N/A | $19.41 |
| P/E Ratio | ★ N/A | $76.27 |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $9.45 | $98.90 |
| 52 Week High | $10.65 | $238.31 |
| Indicator | DNP | LGND |
|---|---|---|
| Relative Strength Index (RSI) | 63.37 | 62.26 |
| Support Level | $9.96 | $180.85 |
| Resistance Level | $10.65 | $227.92 |
| Average True Range (ATR) | 0.13 | 8.74 |
| MACD | 0.02 | 1.97 |
| Stochastic Oscillator | 92.71 | 74.64 |
DNP Select Income Fund Inc is a closed-ended investment management fund. Its investment objectives are current income and long-term growth of income, with capital appreciation as a secondary objective. The Fund seeks to achieve its investment objectives by investing mainly in a diversified portfolio of equity and fixed-income securities of companies in the public utilities industry. Under normal market conditions, more than 65% of the Fund's total assets are invested in securities of public utility companies engaged in the production, transmission, or distribution of electric energy, gas, or telephone services.
Ligand Pharmaceuticals Inc is a biopharmaceutical company focused on developing and acquiring technologies that aid in creating medicine. The company has partnerships and license agreements with various pharmaceutical and biotechnology companies. Ligand's business model is based on drug discovery, early-stage drug development, product reformulation, and partnerships. The company's revenue consists of three primary elements: royalties from commercialized products, license and milestone payments, and sale of its trademarked Captisol material.